AUTHOR=Xie Mengzhang , Huang Qi , Gong Taojun , Wang Yitian , Li Zhuangzhuang , Lu Minxun , Luo Yi , Min Li , Zhou Yong , Tu Chongqi 

TITLE=Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis

JOURNAL=Frontiers in Oncology

VOLUME=Volume 14 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1399574

DOI=10.3389/fonc.2024.1399574

ISSN=2234-943X

ABSTRACT=Desmoid fibromatosis is a formidable fibroblastic neoplasm known for its heightened tendency for local recurrence. Anlotinib, a novel multitargeted angiogenesis inhibitor, represents a novel approach for targeted therapy. We retrospectively enrolled 66 patients. Anlotinib was initiated at a daily dose of 12 mg and adjusted based on drugrelated adverse effects. Progression-free survival was the primary endpoint. In total, sixty-six (25 men and 41 women) consecutive patients were enrolled. No patients achieved a complete response; however, fourteen patients (21.21%) exhibited a partial response, while forty-six patients (70%) experienced disease stability.Progressive disease was observed in 6 patients (9.10%), and the progression-free survival rates at 12 and 36months were 89.71% and 82.81%, respectively. The disease control rate was 90.91%, while the objective response rate was 21.21%. Anlotinib is effective in managing recurrent and symptomatic patients with desmoid fibromatosis. Our results also suggested that postoperative anlotinib may reduce recurrence. However, it's toxicity is associated with a Anlotinib in Desmoid Fibromatosis 3 greater risk of hand-foot skin reaction and hypertension. Therefore, given that 41.67% of patients were subjected to dose adjustments associated with the initial dose of 12 mg, implementing dosage reductions may help balance efficacy with side effects.